Alpha-synuclein and transgenic mouse models

Identified as the cause of some familial forms of Parkinson disease (PD) and as one of the major component of Lewy bodies, alpha-synuclein (alpha-syn) became the molecular hallmark of several neurodegenerative conditions now designated as synucleinopathies. Transgenic models have been generated to elucidate its physiological and pathologic roles. Although none of the lines created display dopaminergic neuronal death in the substantia nigra, the models recapitulate some features of synucleinopathies and are useful to study the potential pathogenic role of alpha-synuclein and its molecular partners. This review describes the different alpha-synuclein transgenic models, their clinical relevance to synucleinopathies, and their further utilization to understand the disease process.

[1]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[2]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[3]  S. Daniel,et al.  The pathophysiology of parkinsonism in multiple system atrophy , 1995, European journal of neurology.

[4]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[5]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[6]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[7]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[8]  Christopher A. Ross,et al.  Immunocytochemical localization of synphilin-1, an α-synuclein-associated protein, in neurodegenerative disorders , 2002, Acta Neuropathologica.

[9]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[10]  P. Lansbury,et al.  Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.

[11]  R. Morris,et al.  Spatial learning is unimpaired in mice containing a deletion of the alpha‐synuclein locus , 2002, The European journal of neuroscience.

[12]  C. Lavedan.  The synuclein family. , 1998, Genome research.

[13]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[14]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[15]  B. Sommer,et al.  Mouse models of α-synucleinopathy and Lewy pathology , 2000, Experimental Gerontology.

[16]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[17]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[18]  H. Budka,et al.  Accumulation of 14‐3‐3 proteins in glial cytoplasmic inclusions in multiple system atrophy , 2002, Annals of neurology.

[19]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[20]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[21]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[22]  D. Hernandez,et al.  Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. , 2003, Human molecular genetics.

[23]  G. Sobue,et al.  A novel centrosomal ring-finger protein, dorfin, mediates ubiquitin ligase activity. , 2001, Biochemical and biophysical research communications.

[24]  R. Krüger,et al.  Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.

[25]  A. Dehejia,et al.  Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. , 2001, Genome research.

[26]  M. Goedert,et al.  The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .

[27]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[28]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[29]  K. Arima,et al.  Tubulin Seeds α-Synuclein Fibril Formation* , 2002, The Journal of Biological Chemistry.

[30]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[31]  I. McKeith.  Dementia with Lewy bodies , 2002, British Journal of Psychiatry.

[32]  P. Lantos,et al.  The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. , 1994, Brain : a journal of neurology.

[33]  A. Lees,et al.  Lewy body cortical involvement may not always predict dementia in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[34]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[35]  G. Sobue,et al.  Dorfin Localizes to Lewy Bodies and Ubiquitylates Synphilin-1* , 2003, Journal of Biological Chemistry.

[36]  G. Sobue,et al.  Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. , 2003, The American journal of pathology.

[37]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Shigeo Hirai,et al.  NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.

[39]  M. Farrer,et al.  Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter , 2001, Neurobiology of Disease.

[40]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[42]  H. Budka,et al.  14‐3‐3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains , 2002, Journal of neuropathology and experimental neurology.

[43]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[45]  G. Sobue,et al.  Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease , 2001, Neuropathology and applied neurobiology.

[46]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[47]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[48]  S. Hayashi,et al.  NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains , 2000, Acta Neuropathologica.

[49]  A. Lees,et al.  Striatonigral degeneration. A clinicopathological study. , 1990, Brain : a journal of neurology.

[50]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[51]  Georg Auburger,et al.  Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation , 2003, Molecular and Cellular Neuroscience.

[52]  E. Tolosa,et al.  Clinical overview of the synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.

[53]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[54]  T. Südhof,et al.  Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2003, Neuroscience.

[55]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[56]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[57]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[58]  Kenji Ikeda,et al.  Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein , 1999, Neuroscience Letters.

[59]  D. Burn,et al.  The pathogenesis of multiple system atrophy: Past, present, and future , 2000, Movement disorders : official journal of the Movement Disorder Society.

[60]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[61]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[62]  J. R. Menezes,et al.  Synphilin-1 Is Developmentally Localized to Synaptic Terminals, and Its Association with Synaptic Vesicles Is Modulated by α-Synuclein* , 2002, The Journal of Biological Chemistry.

[63]  Hitoshi Takahashi,et al.  Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy , 1998, Acta Neuropathologica.

[64]  Minh N. H. Nguyen,et al.  Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice , 2003, Science.

[65]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[66]  S. Murayama,et al.  Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.

[67]  J. Growdon,et al.  Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.

[68]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[69]  C. Specht,et al.  Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice , 2001, BMC Neuroscience.